Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RLAY Relay Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RLAY
Price (delayed)
$3
Market cap
$514.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.2
Enterprise value
$465.83M
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Highlights
The EPS has increased by 17% year-on-year and by 7% since the previous quarter
The debt has contracted by 10% YoY and by 2.8% from the previous quarter
RLAY's quick ratio is up by 25% since the previous quarter but it is down by 5% year-on-year
Relay Therapeutics's revenue has plunged by 78% YoY and by 23% from the previous quarter
RLAY's gross profit has dropped by 78% year-on-year and by 23% since the previous quarter
Key stats
What are the main financial stats of RLAY
Market
Valuations
Earnings
Shares outstanding
171.44M
Market cap
$514.33M
Enterprise value
$465.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
66.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.66
Revenue
$7.68M
Gross profit
$7.68M
Operating income
-$378.35M
Net income
-$333.39M
EBIT
-$333.39M
EBITDA
-$328.11M
Free cash flow
-$272.62M
Per share
Balance sheet
Liquidity
EPS
-$2.2
EPS diluted
-$2.2
Free cash flow per share
-$1.61
Book value per share
$4.25
Revenue per share
$0.05
TBVPS
$4.71
Total assets
$799.36M
Total liabilities
$78.28M
Debt
$47.16M
Equity
$721.08M
Working capital
$702.61M
Debt to equity
0.07
Current ratio
19.96
Quick ratio
19.23
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-4,272.8%
Gross margin
100%
Net margin
-4,341.5%
Operating margin
-4,927%
Return on assets
-39.5%
Return on equity
-44.2%
Return on invested capital
-46.5%
Return on capital employed
-43.7%
Return on sales
-4,341.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLAY stock price
How has the Relay Therapeutics stock price performed over time
Intraday
0%
1 week
-7.69%
1 month
30.43%
1 year
-52.46%
YTD
-27.18%
QTD
14.5%
Financial performance
How have Relay Therapeutics's revenue and profit performed over time
Revenue
$7.68M
Gross profit
$7.68M
Operating income
-$378.35M
Net income
-$333.39M
Gross margin
100%
Net margin
-4,341.5%
Relay Therapeutics's revenue has plunged by 78% YoY and by 23% from the previous quarter
RLAY's gross profit has dropped by 78% year-on-year and by 23% since the previous quarter
The net margin has contracted by 29% from the previous quarter
Relay Therapeutics's operating margin has decreased by 28% from the previous quarter
Price vs fundamentals
How does RLAY's price correlate with its fundamentals
Growth
What is Relay Therapeutics's growth rate over time
Valuation
What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
0.71
P/S
66.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.66
The EPS has increased by 17% year-on-year and by 7% since the previous quarter
The P/B is 74% lower than the 5-year quarterly average of 2.7 and 29% lower than the last 4 quarters average of 1.0
The equity has declined by 7% since the previous quarter and by 3.3% year-on-year
The stock's price to sales (P/S) is 88% less than its 5-year quarterly average of 535.8 but 10% more than its last 4 quarters average of 60.1
Relay Therapeutics's revenue has plunged by 78% YoY and by 23% from the previous quarter
Efficiency
How efficient is Relay Therapeutics business performance
The return on sales has declined by 29% since the previous quarter
The ROA is down by 7% YoY
The return on invested capital has declined by 4.7% year-on-year
The company's return on equity fell by 3.5% YoY
Dividends
What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLAY.
Financial health
How did Relay Therapeutics financials performed over time
RLAY's current ratio is up by 25% since the previous quarter but it is down by 3.7% year-on-year
RLAY's quick ratio is up by 25% since the previous quarter but it is down by 5% year-on-year
The debt is 93% less than the equity
Relay Therapeutics's debt to equity has increased by 17% from the previous quarter
The debt has contracted by 10% YoY and by 2.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.